3rd Targeted Radiopharmaceuticals (TRP) Summit
Start Date: Dec 7th, 2021 09:00
End Date: Dec 9th, 2021 17:30
Location: Berlin, Germany
.png)
The 3rd Targeted Radiopharmaceuticals (TRP) Summit  returns at a crucial time for the entire industry. Spurred on by positive Phase III VISION trial data, there has been huge research investment, on both sides of the Atlantic, on how to deliver radiation therapy directly and specifically to tumours.
For the 2021 edition of this conference, there will be the opportunity to attend either in-person in Berlin or remotely via a dedicated digital networking platform with all the access to the conference content.
You can expect a wider array of insights from recent case studies to help you accelerate the development of the next generation of radioligand therapies from clinical approval to commercialisation.
As the only industry-led platform for discussing challenges and opportunities facing developers of theranostic radioligand therapies, we strive to tackle topics that are on every drug developer’s mind:
- How do we identify and validate new targets?
- Can we combine Targeted Radiopharmaceuticals with immunotherapy or other targeted oncology methods?
- How do we improve current clinical design methodologies and patient selection strategies?
- Where can improvements be made to the current supply and fulfilment models?
To see the wide variety of talks, panels, and speakers tackling these issues, download the full event guide here
EFOMP presence on page 10 of PDF attached
Medical Physics and quantitative dosimetry : Unlocking the Potential of Radionuclide Therapies
• Dosimetry allows improved targeting of tumours with radionuclide therapy and sparing of healthy organs and tissues improving patient experience and outcomes
• Medical physicists are willing to train and to deliver dosimetry, at start up and in clinical phase for existing and new therapeutic radionuclides
• Having access to quantitative information on radiation dose to affected tissue will unlock the power of new and existing stand alone and combined therapies by predicting radiobiological response